These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. The Effect of Pregnancy and Inflammatory Bowel Disease on the Pharmacokinetics of Drugs Related to Inflammatory Bowel Disease-A Systematic Literature Review. Wiersma TK; Visschedijk MC; de Boer NK; Lub-de Hooge MN; Prins JR; Touw DJ; Mian P Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745812 [TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis. Singh S; Garg SK; Pardi DS; Wang Z; Murad MH; Loftus EV Mayo Clin Proc; 2014 Dec; 89(12):1621-35. PubMed ID: 25441399 [TBL] [Abstract][Full Text] [Related]
11. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar. Buurman DJ; Blokzijl T; Festen EAM; Pham BT; Faber KN; Brouwer E; Dijkstra G PLoS One; 2018; 13(12):e0208922. PubMed ID: 30533022 [TBL] [Abstract][Full Text] [Related]
12. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Gisbert JP; Marín AC; McNicholl AG; Chaparro M Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884 [TBL] [Abstract][Full Text] [Related]
13. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. Matro R; Martin CF; Wolf D; Shah SA; Mahadevan U Gastroenterology; 2018 Sep; 155(3):696-704. PubMed ID: 29857090 [TBL] [Abstract][Full Text] [Related]
14. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829 [TBL] [Abstract][Full Text] [Related]
15. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Mahadevan U; Cucchiara S; Hyams JS; Steinwurz F; Nuti F; Travis SP; Sandborn WJ; Colombel JF Am J Gastroenterol; 2011 Feb; 106(2):214-23; quiz 224. PubMed ID: 21157441 [TBL] [Abstract][Full Text] [Related]
16. Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease. Grišić AM; Dorn-Rasmussen M; Ungar B; Brynskov J; Ilvemark JFKF; Bolstad N; Warren DJ; Ainsworth MA; Huisinga W; Ben-Horin S; Kloft C; Steenholdt C United European Gastroenterol J; 2021 Feb; 9(1):91-101. PubMed ID: 33079627 [TBL] [Abstract][Full Text] [Related]